ontorpacept intratumoral (TTI 621 intratumoral) / Pfizer - LARVOL DELTA

Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting (GlobeNewswire) - “Trillium Therapeutics Inc…announced the presentation of clinical data at the upcoming American Society of Hematology (ASH) Annual Meeting, which is being held virtually from December 5-8, 2020.”

Clinical data • Hematological Malignancies • Lymphoma • Oncology

Trillium Therapeutics Receives Notices of Allowance From U.S. Patent and Trademark Office (GlobeNewswire) - “Trillium Therapeutics Inc…announced today that it has received Notices of Allowance from the United States Patent and Trademark Office for two patent applications covering the use of SIRPaFc for the treatment of cancer, U.S. Patent Application No. 13/320,629…and U.S. Patent Application No. 15/962,540….Trillium has two SIRPaFc biologics, TTI-621 and TTI-622, in clinical development. Both therapeutics target CD47, a ‘don’t eat me’ signal that cancer cells use to evade immune destruction. The ‘629 method of use Application provides coverage for the use of SIRPaFc biologics to treat all CD47+ cancer cells and tumours, including hematologic and solid cancers.”

Patent • Hematological Malignancies • Oncology • Solid Tumor

Trillium Announces Pricing of US$130 Million Public Offering of Common Shares (Trillium Therapeutics Press Release) - "Trillium Therapeutics...announced that it has priced its previously announced underwritten public offering of 10,000,000 common shares (the 'Common Shares') of the Company (the 'Offering'). The Common Shares are being sold at a public offering price of US$13.00 per Common Share...The gross proceeds to the Company from the Offering are expected to be approximately US$130 million, before deducting underwriting discounts and commissions and other estimated offering expenses...The Company intends to use the net proceeds of the Offering for its ongoing and planned clinical trials for its CD47 program, including drug supply and for working capital and general corporate purposes."

Financing • Oncology